Aptose Biosciences, Inc. (APTO)

Market Cap	55.34M
Revenue (ttm)	n/a
Net Income (ttm)	-57.70M
Shares Out	93.01M
EPS (ttm)	-0.67
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	148,555
Open	0.570
Previous Close	0.594
Day's Range	0.570 - 0.598
52-Week Range	0.540 - 2.780
Beta	1.39
Analysts	Buy
Price Target	4.64 (+679.8%)
Earnings Date	Nov 9, 2022

About APTO

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and HM43239 that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops ...

• Industry: Biotechnology
• Founded: 1986
• CEO: William Rice
• Employees: 41
• Stock Exchange: NASDAQ
• Ticker Symbol: APTO

Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for APTO stock is "Buy." The 12-month stock price forecast is 4.64, which is an increase of 679.83% from the latest price.

Price Target

$4.64

(679.83% upside)

Analyst Consensus: Buy

Stock Forecasts